Derivatives and Quantitative Strategist

Gaudenz Schneider

Equity Bottom-Up

<ul>
<li>
Context: Friday’s sell-off occurred after the Australian market closed, but several ASX-listed companies were swept up in the decline through dual listings or U.S.-traded ADRs.</li>
<li>
This Insight looks at the impact on prominent <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200</a> constituents — including BHP, CSL, and major banks. While some companies showed limited movement, others, such as BHP, experienced sharper declines.</li>
<li>
Why Read: Understand where the Australian market might be headed when trading resumes after the weekend.</li>
</ul>



Context: Friday’s sell-off occurred after the Australian market closed, but several ASX-listed companies were swept up in the decline through dual listings or U.S.-traded ADRs.

This Insight looks at the impact on prominent S&amp;P/ASX 200 constituents — including BHP, CSL, and major banks. While some companies showed limited movement, others, such as BHP, experienced sharper declines.

Why Read: Understand where the Australian market might be headed when trading resumes after the weekend.


BHP (BHP AU/US) And Woodside (WDS AU/US) Slide as U.S. Sell-Off Spills Into Australian Stocks

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> expects to report FY26 underlying net profit of $435–460M, an 11–17% increase on FY25, up 5–11% on a comparative (cloud adjusted) basis.</li>
<li>The Nucleus Nexa System has been launched in Europe and Asia Pacific in mid-June 2025 and will be launched in the U.S. by the end of Q1FY26.</li>
<li>The company expects strong FY26 revenue growth in developed markets from the launch of the new Nucleus Nexa implant, with overall revenue and earnings growth weighted to the second half.</li>
</ul>



Cochlear Ltd (COH AU) expects to report FY26 underlying net profit of $435–460M, an 11–17% increase on FY25, up 5–11% on a comparative (cloud adjusted) basis.
The Nucleus Nexa System has been launched in Europe and Asia Pacific in mid-June 2025 and will be launched in the U.S. by the end of Q1FY26.
The company expects strong FY26 revenue growth in developed markets from the launch of the new Nucleus Nexa implant, with overall revenue and earnings growth weighted to the second half.


Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Sonic Healthcare's latest half-year financial results for the period ending December 31, 2024, provide a comprehensive overview of the company's recovery and growth trajectory in the post-pandemic world.</li><li>The company has displayed a substantial rebound, with significant improvement across key financial metrics, guided by strong organic growth and tight cost control measures, particularly in labor costs.</li><li>Revenue for the period was reported at AUD 4.669 billion, an 8% increase compared to the previous period.</li></ul>

Sonic Healthcare's latest half-year financial results for the period ending December 31, 2024, provide a comprehensive overview of the company's recovery and growth trajectory in the post-pandemic world.The company has displayed a substantial rebound, with significant improvement across key financial metrics, guided by strong organic growth and tight cost control measures, particularly in labor costs.Revenue for the period was reported at AUD 4.669 billion, an 8% increase compared to the previous period.

Sonic Healthcare: Initiation of Coverage- Inside the FY ‘26 Ramp-Up That Could Up Its Diagnostics Game!

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul><li>Extra Edition of the Broker Call Report</li></ul>

Australian Broker Call *Extra* Edition - Jul 07, 2025

<ul>
<li>Update on changes to and revisions of analysts' Best Ideas and Conviction Calls, as well as Model Portfolio compositions</li>
</ul>


Update on changes to and revisions of analysts' Best Ideas and Conviction Calls, as well as Model Portfolio compositions


Rudi's View: CBA, Life360, ResMed, Zip & More

Australia

Sonic Healthcare Limited is a medical diagnostics company with operations in Australia, New Zealand, and Europe.  The Company provides a comprehensive range of pathology and diagnostic imaging services to medical practitioners, hospitals and their patients along with providing administrative services and facilities to medical practitioners.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sonic Healthcare (SHL AU)

BHP (BHP AU/US) And Woodside (WDS AU/US) Slide as U.S. Sell-Off Spills Into Australian Stocks

Friday’s U.S. market rout pushed dual-listed Australian stocks lower, with BHP and Woodside among the biggest movers. US-traded ADRs and futures...

Gaudenz Schneider

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Tina Banerjee

Sonic Healthcare: Initiation of Coverage- Inside the FY ‘26 Ramp-Up That Could Up Its Diagnostics Game!

Sonic Healthcare's latest half-year financial results for the period ending December 31, 2024, provide a comprehensive overview of the company's...

Baptista Research

Australian Broker Call Extra Edition - Jul 07, 2025

Extra Edition of the Broker Call Report

FNArena

Rudi's View: CBA, Life360, ResMed, Zip & More

Update on changes to and revisions of analysts' Best Ideas and Conviction Calls, as well as Model Portfolio compositions

FNArena

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BHP (BHP AU/US) And Woodside (WDS AU/US) Slide as U.S. Sell-Off Spills Into Australian Stocks

Friday’s U.S. market rout pushed dual-listed Australian stocks lower, with BHP and Woodside among the biggest movers. US-traded ADRs and futures...

Gaudenz Schneider

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

​Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Tina Banerjee

Sonic Healthcare: Initiation of Coverage- Inside the FY ‘26 Ramp-Up That Could Up Its Diagnostics Game!

Sonic Healthcare's latest half-year financial results for the period ending December 31, 2024, provide a comprehensive overview of the company's...

Baptista Research

Australian Broker Call *Extra* Edition - Jul 07, 2025

Extra Edition of the Broker Call Report

FNArena

Rudi's View: CBA, Life360, ResMed, Zip & More

Update on changes to and revisions of analysts' Best Ideas and Conviction Calls, as well as Model Portfolio compositions

FNArena

Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Australian Broker Call Extra Edition - Jul 07, 2025